Toxoid vaccine market is expected to grow at a significant CAGR during the forecast period. The key companies across the globe are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers and acquisitions, geographical expansion, new product launch, and product innovation to remain competitive in the marketplace. For instance, in March 2020, In December 2019, Panacea Biotec, received an award worth $24.3 million from U. N nations (UNICEF and PAHO) for its supply of its WHO prequalified Pentavalent Vaccine. The vaccine protects children from Diphtheria, Tetanus, Pertussis, hepatitis B, and invasive infections caused by Haemophilus Influenza Type b.
Apart from this, in May 2021, GlaxoSmithKline and Samsung partnered to provide GSK with additional capacity to manufacture and supply GSK’s innovative biopharmaceutical therapies. The agreement will supplement GSK’s existing manufacturing network. Moreover, in April 2021, AstraZeneca proposed acquisition of Alexion Pharmaceuticals, Inc received US Federal Trade Commercial clearance. In addition, in June 2021, Merck acquired the spinoff of Organon & Co. Merck. The acquisition will allow Merck to create two patient-focused companies with enhanced strategies, operational focus, and improved financial profiles. In October 2018, Emergent Biosolutions Inc. acquired PaxVax to expand its portfolio of marketed and pipeline products, expand its manufacturing capabilities and strengthen its presence in the market.
The factor contributing to the growth of the market is the rising prevalence of tetanus. According to the Center for disease control and prevention, 38,000 people died from tetanus in 2017, across the globe, and around half (49%) were younger than five years old. Additionally, the vaccine against tetanus allowed progress in controlling the disease. 89% reduction in tetanus cases and deaths resulted since 1990. Thus, the usefulness of vaccines is contributing to the growth of the market.
To Request a Sample of our Report on Toxoid Vaccine Market: https://www.omrglobal.com/request-sample/toxoid-vaccine-market-size
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Pfizer Inc., Merck KGaA, and GlaxoSmithKline PLC, among others.
Toxoid Vaccine Market Report Segmentation
By Type
- Monovalent Tetanus Toxoid (TT)
- Diphtheria, Tetanus, and Pertussis (DTaP)
- Diphtheria and Tetanus (DT)
By End-User
- Hospitals and Clinics
- Government Organizations
- Others
A full Report of Toxoid Vaccine Market is Available @ https://www.omrglobal.com/industry-reports/toxoid-vaccine-market-size
Toxoid Vaccine Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/toxoid-vaccine-market-size
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
